Why Rezo Therapeutics is interesting

Rezo spun out Krogan/Shokat lab work integrating proteomics and genetics into druggable network maps — a16z Bio co-led the launch round with SR One.

Key facts

• Series A (Nov 2022): $78M co-led by SR One, a16z Bio + Health, and Norwest (Rezo press)
• Co-investors not in VCT directory: SR One, SV Angel, Liquid 2 Ventures, Hawktail
• Source: https://rezotx.com/rezo-founded-by-renowned-ucsf-scientists-launches-with-78-million-series-a-to-advance-pipeline-of-precision-therapeutics-based-on-groundbreaking-integrated-disease-network-mapping-platform/

Investors in our directory

Funds linked from Rezo Therapeutics's profile — open a fund page for stage focus and related deal articles.

Industries

Industry hub pages are rolling out from our fund-derived baseline taxonomy.

Related funding articles

Venture Capital Tracker pieces that cover Rezo Therapeutics's financing or category context.

• a16z Portfolio Companies on Fire in 2026: AI, American Dynamism & More